CAMP4 Therapeutics Corporation Capital Expenditures Incurred but Not yet Paid
CAMP4 Therapeutics Corporation (CAMP) reported Capital Expenditures Incurred but Not yet Paid of $400.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-13
- CAMP4 Therapeutics Corporation capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $298.00K.
- CAMP4 Therapeutics Corporation capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $102.00K.
- CAMP4 Therapeutics Corporation capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $0.00.
- CAMP4 Therapeutics Corporation capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- CAMP4 Therapeutics Corporation capital expenditures incurred but not yet paid for fiscal 2025 was $203.00K.
- CAMP4 Therapeutics Corporation capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CAMP4 Therapeutics Corporation capital expenditures incurred but not yet paid for fiscal 2023 was $12.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $298.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $400.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $102.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $203.00K 10-K · filed 2026-03-05 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 | |||
| 2024-03-31 | $151.00K 10-Q · filed 2025-05-13 | $107.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $12.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $56.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |